Management of myoclonus with oral liposomal reduced glutathione

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione formulated from said reduced glutathione in liposomal formulation being formulated in a process whose temperature does not exceed 50 degrees C., and which process utilizes mixing of a first container of lecithin and glycerin, and a second container of components of at least deionized water and glutathione (reduced) and upon mixing at a temperature not in excess of 50 degrees, said reduced glutathione in liposomal formulation thereby being capable of storage at room temperature for at least one month with at least 50% of original reduced glutathione.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione in a form which can be taken orally or absorbed across the mucosa of the nose, mouth, gastrointestinal tract.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione in a form which can be absorbed by topical application for transdermal administration.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of reduced glutathione by intravenous infusion

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione;
• and
• administration of itraconazole.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione;
• and
• administration of amphoteracin.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione;
• and
• administration of fluconazole.

A method of treatment of patients having myoclonus-related symptoms as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione;
• and
• administration of voriconazole.

A method of treatment for patients having myoclonus-related neurodegenerative disease as a result of mold toxin exposure comprising:

• administration of an oral liposomal preparation of reduced glutathione;
• and
• administration of voriconazole.